Research Use Only. Products listed are not for human or animal consumption. Statements have not been evaluated by the FDA.View full disclaimers →
.png&w=750&q=75)
Dihexa is a synthetic compound derived from angiotensin IV, developed at Washington State University and studied as a procognitive agent acting through the hepatocyte growth factor and c-Met system. The foundational research describing this mechanism was retracted in 2025 for data fabrication. No human clinical trial of dihexa has been published.
Supplier listings
Form
Show prices as
Size
8 listings · Dihexa
In stock10mgseen 8w ago
In stock5mgseen 7w ago
In stock10mgseen 4w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
Out of stock10mgseen 3w ago
Out of stock10mgseen 7w ago
Overview
Dihexa is a synthetic compound derived from angiotensin IV, developed at Washington State University and studied as a procognitive agent acting through the hepatocyte growth factor and c-Met system. The foundational research describing this mechanism was retracted in 2025 for data fabrication. No human clinical trial of dihexa has been published.
What the research reports
Outcomes described across the published Dihexa literature and ongoing study. Read each as research context rather than a promised personal result.
Synaptogenesis animal study
Claims of new synaptic connection formation originate primarily from a 2014 paper that was retracted in 2025 for fabricated data. No independently verified study currently supports this specific finding.
HGF and c-Met pathway work
Dihexa's proposed mechanism involves the hepatocyte growth factor and c-Met receptor system. The foundational paper establishing this mechanism was retracted in 2025 for fabricated data; the mechanism should be considered unconfirmed pending independent replication.
High laboratory potency data
Active at very low concentrations in cell based synaptogenesis assays, which is a measure of potency rather than of clinical effect. Reported in research settings.
Memory model animal study
Studied in animal models of impaired cognition, including scopolamine induced amnesia and Alzheimer's disease models. Described in the research record.
Neuroprotection study note
Reviews propose neuroprotective potential through the same growth factor pathway, though no controlled human data supports this. Reported in research settings.
Clinical evidence
The published Dihexa record, labeled by strength so you can see what is settled and what is still emerging.
A foundational 2014 paper describing Dihexa's HGF/c-Met mechanism was retracted in 2025 following a Washington State University investigation that found fabricated data in the original figures. A related 2012 paper by the same research group was also retracted. The mechanistic basis for Dihexa's procognitive claims should be treated as unsettled. Source: link to the retraction notice itself,
SourceAn animal study in 40 rats found that an angiotensin IV analogue did not protect against 3-nitropropionic acid induced Huntington's like symptoms. Reported in the cited paper.
SourceA systematic review of experimental studies examined cognitive effects of angiotensin IV and angiotensin 1-7 across the available animal literature. Reported in the cited paper.
SourceInteractions
Questions
